PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Protalix BioTherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOODS | $51.80M | $52.98M | $40.42M | $25.29M | $16.75M | $16.24M | $15.87M | $8.98M | $19.24M | $9.20M | 98.2% | -2.2% |
| LICENSE AND R&D SERVICES | $942.00K | $418.00K | $25.08M | $22.35M | $21.60M | $46.66M | $38.83M | $25.26M | $1.84M | – | 1.8% | +125.4% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil | – | – | – | – | – | – | $9.14M | $3.66M | $7.06M | $3.97M | – | – |
| Pfizer [Member] | – | – | – | – | – | – | $6.72M | $5.32M | $12.18M | – | – | – |
From the segment and revenue-disaggregation notes of Protalix BioTherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.